You are here

Dr. Susan Love


LCIS is an acronym for lobular carcinoma in situ. LCIS is typically diagnosed after a breast biopsy. It is not breast cancer, but it does increase breast cancer risk. In this video, you will learn about LCIS and how it is treated.


DCIS is an acronym for ductal carcinoma in situ. DCIS is a precancer that is usually found on a mammogram. In this video, you will learn how DCIS is diagnosed and treated.

Cancer & Immunology

In this video you will learn about cancer drugs that help your immune system kill cancer cells. You will also learn about vaccines that teach the body's immune system to wipe out viruses that can cause cancer.

Leadership & Staff

Board of Directors

Dr. Susan Love Research Foundation's Board of Directors advises, assists, and aids in our efforts to be at the forefront of breast cancer research and to promote education and advocacy in the community.

Dr. Susan Love

Dr. Susan Love

Susan M. Love, MD, MBA has dedicated her professional life to the eradication of breast cancer. What began as a career in the 1970's quickly turned into a mission and as chief visionary officer of Dr. Susan Love Research Foundation (DSLRF), Dr. Love oversees an active research program centered on breast cancer cause and prevention.

Research Worth Watching: the Precision Medicine Project

Usually I use this space to tell you about some new molecular finding that changes the way we think about breast cancer. But after two trips to the East Coast this month to talk about the President's Precision Medicine Project, I thought I should bring you up to date on what this is and what it might mean for all of us. The basic concept of precision medicine is that our current ability to map a person's genome, as well as the mutations in their cancer or related to another disease, gives us a new opportunity to figure out how to precisely treat a disease.

Research Worth Watching: Digging into Metastatic Disease

Much of the discussion and debate about breast cancer is currently over issues like screening guidelines, risk, and prophylactic bilateral mastectomies. This focus on risk reduction and early detection can lull us into a false sense of security, suggesting that if we just do this early stuff right we can prevent all breast cancer deaths. But women and men still die from breast cancer even after screening, bilateral mastectomies, 'precision medicine,' and targeted therapy! Why? Because we don't yet know enough about metastases.